These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 7407787

  • 1. Animal models of cancer immunotherapy: questions of relevance.
    Weiss DW.
    Cancer Treat Rep; 1980; 64(2-3):481-5. PubMed ID: 7407787
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New possibilities for cancer therapy with advances in cancer immunology.
    MacLean GD, Longenecker BM.
    Can J Oncol; 1994 Apr; 4(2):249-54. PubMed ID: 7516257
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identifying tumor antigens in endocrine malignancies.
    Wuttke M, Papewalis C, Jacobs B, Schott M.
    Trends Endocrinol Metab; 2009 Apr; 20(3):122-9. PubMed ID: 19269848
    [Abstract] [Full Text] [Related]

  • 11. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.
    Talmadge JE, Oldham RK, Fidler IJ.
    J Biol Response Mod; 1984 Apr; 3(1):88-109. PubMed ID: 6707701
    [Abstract] [Full Text] [Related]

  • 12. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy].
    Van den Eynde B.
    Bull Mem Acad R Med Belg; 2007 Apr; 162(5-6):352-6. PubMed ID: 18405005
    [Abstract] [Full Text] [Related]

  • 13. The potential of melanoma antigen expression in cancer therapy.
    Gillespie AM, Coleman RE.
    Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
    [Abstract] [Full Text] [Related]

  • 14. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B, Siegel SE, Kaiser HE.
    Anticancer Res; 1996 Aug; 16(2):661-74. PubMed ID: 8687112
    [Abstract] [Full Text] [Related]

  • 15. [The function of tumor specific antigen (MAGE) in tumor immunotherapy].
    Fang JB, Wang L.
    Sheng Li Ke Xue Jin Zhan; 2005 Jul; 36(3):273-5. PubMed ID: 16270835
    [No Abstract] [Full Text] [Related]

  • 16. Analyses and perspectives in cancer immunotherapy.
    Nguyen van Binh P, Duc HT.
    Biomed Pharmacother; 2006 Nov; 60(9):621-8. PubMed ID: 16978826
    [Abstract] [Full Text] [Related]

  • 17. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A, Butterfield LH, Glaspy JA, Economou JS.
    J Clin Oncol; 2003 Jun 15; 21(12):2415-32. PubMed ID: 12805342
    [Abstract] [Full Text] [Related]

  • 18. Tumor immunity and immunotherapy.
    Boura P, Kountouras J, Lygidakis NJ.
    Hepatogastroenterology; 2001 Jun 15; 48(40):1040-4. PubMed ID: 11490795
    [Abstract] [Full Text] [Related]

  • 19. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug 15; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 20. A fresh look at tumor immunosurveillance and immunotherapy.
    Smyth MJ, Godfrey DI, Trapani JA.
    Nat Immunol; 2001 Apr 15; 2(4):293-9. PubMed ID: 11276199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.